Qdenga Becomes India’s First Approved Dengue Vaccine

Context: The article examines the approval of India’s first dengue vaccine and why vaccination must complement rather than replace vector surveillance and mosquito control.

Source: “UPSC Key: Dengue vaccine, Right to protest, and EPF scheme,” The Indian Express, July 21, 2026.

Core Points

• India’s drug regulator has approved Takeda’s Qdenga, or TAK-003, as the country’s first dengue vaccine.
• It is a live-attenuated tetravalent vaccine designed to produce immunity against DENV-1, DENV-2, DENV-3 and DENV-4.
• The Indian approval covers people aged four to 60 years, irrespective of previous dengue infection.
• It is administered subcutaneously in two 0.5-mL doses separated by three months.
• A Phase III trial reported 80.2% efficacy against virologically confirmed dengue during the year following the second dose.
• Approval does not mean immediate inclusion in a public immunisation programme. Price, supply, epidemiology, safety monitoring and cost-effectiveness must be assessed separately.
• Protection may vary by serotype, age and previous exposure; post-marketing surveillance will therefore remain important.
• Vaccination cannot independently stop outbreaks while infected Aedes mosquitoes continue circulating.
• Biological E’s manufacturing partnership is intended to support production of up to 50 million doses annually.

Prelims Relevance

• Dengue is caused by a flavivirus and has four principal serotypes.
• Aedes aegypti and Aedes albopictus are important dengue vectors.
• A live-attenuated vaccine contains weakened, replication-capable forms of a pathogen.
• A tetravalent vaccine is designed to provide protection against four antigenic types.

Mains Relevance

• GS II: Public health, vaccine access, disease surveillance and preventive healthcare.
• GS III: Vaccine technology, clinical trials, domestic manufacturing and pharmacovigilance.

Supporting Fact Box

• Aedes mosquitoes commonly breed in small collections of clean or relatively clean water and are active mainly during daylight hours.
• Infection with one dengue serotype generally produces long-term immunity to that serotype but not equivalent permanent protection against the other three.
• WHO prequalification permits procurement by UN agencies; it does not replace national regulatory approval.
• WHO’s public-health recommendation targets children aged 6–16 years in settings with high dengue-transmission intensity, which is narrower than India’s marketing authorisation.